Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Trial

Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Trial

The DARE-AF trial demonstrated that among patients with persistent atrial fibrillation (AF) undergoing catheter ablation, three months of treatment with dapagliflozin did not reduce early arrhythmia recurrence, according to a study presented by Dr. Zixu Zhao, Beijing Anzhen Hospital, China, in the Late-Breaking Science session at the AHA Scientific Sessions 2025.

In the DARE-AF trial, 200 patients with persistent AF who underwent their first catheter ablation be...
Continue reading this article
Select an option below:
Go beyond the guidelines
A portal site of complex catheter intervention techniques
About TCROSS NEWS Global

TCROSS NEWS Global is an online medical journal that provides valuable information on Cardiovascular medicine to medical professionals worldwide.
We bring you the latest findings and trends in all areas of cardiovascular medicine. Please register and subscribe for unlimited access to quality Cardiovascular News!

Introducing the main contents
Conference Reports
Conference Reports
Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!
Complex PCI Cases
Complex PCI Cases
Features case reports on patients with complex lesions encountered in daily clinical practice.
Live Demonstration Courses
Live Demonstration CoursesComing soon
In this section you will find live videos of catheter interventions for complex lesions.
What is TCROSS NEWS GLOBAL?
TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Learn more about TCROSS NEWS Global
This website is automatically translated using Google Translate.

Recommendations

Long-term DAPT Beyond 12 Months After DES Implantation in Patients With Multivessel Coronary Artery Disease: The DAPT-MDV Trial
Long-term DAPT Beyond 12 Months After DES Implantation in Patients With Multivessel Coronary Artery Disease: The DAPT-MDV Trial
AHA 2025
Ticagrelor vs Prasugrel After PCI in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Trial
Ticagrelor vs Prasugrel After PCI in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Trial
AHA 2025
Short Dual Antithrombotic Therapy After PCI In Patients With Atrial Fibrillation: The OPTIMA-AF Trial
Short Dual Antithrombotic Therapy After PCI In Patients With Atrial Fibrillation: The OPTIMA-AF Trial
AHA 2025
The Annual AHA Scientific Sessions 2025 was held in New Orleans
The Annual AHA Scientific Sessions 2025 was held in New Orleans
AHA 2025
PICK UP
Challenging Healthcare Marketing Costs toward Achieving Universal Health Coverage
Special
InsighTCROSS
DCB vs DES in Patients With De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Trials
CCI
DCB vs DES in Patients With De Novo Coronary Artery Disease: A Meta-Analysis of Randomized Trials
Intravascular Imaging-Guided PCI vs CABG in Patients With Left Main or Three-Vessel Disease
JACC Intervention
Intravascular Imaging-Guided PCI vs CABG in Patients With Left Main or Three-Vessel Disease
Outcomes of Orbital Atherectomy for Coronary Calcified Nodules
CCI
Outcomes of Orbital Atherectomy for Coronary Calcified Nodules
Coronary Chronic Total Occlusions Affect Long-Term Prognosis in Heart Failure With Mildly Reduced Ejection Fraction
JAHA
Coronary Chronic Total Occlusions Affect Long-Term Prognosis in Heart Failure With Mildly Reduced Ejection Fraction